Back to all journals
journal articles
EDITORIAL: FROM TRIAL POPULATION TO TREATED POPULATION: WHY EU-ELIGIBLE SUBGROUP ANALYSES MATTER FOR ANTI-AMYLOID IMMUNOTHERAPY
Timo Grimmer
J Prev Alz Dis 2026;8(13)
CITATION:
Timo Grimmer: From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.1016/j.tjpad.2026.100665